---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-007019"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:10:49.124481+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences amends bonus plan; ties CEO payout to FDA approval of simufilam

## Summary
- Amendments require Chairman/President/CEO bonus only if FDA approves simufilam, except in Merger Transaction.
- Compensation Committee set all previously unallocated cash bonuses to zero and rescinded plan on Feb 13, 2025.
- No cash bonuses have been paid to any participant under the CIB Plan through the filing date.
- Changes result from shareholder derivative lawsuit settlement approved by Delaware Court of Chancery on Jan 24, 2025.
- Market cap milestones up to $5B remain; bonuses deferred until Company has sufficient cash for 24 months.

## SEC filing metadata
- accession: 0001437749-25-007019
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774925007019/0001437749-25-007019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774925007019/sava20250310_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-007019
- JSON: https://secwatch.observer/filing/0001437749-25-007019.json
- Plain text: https://secwatch.observer/filing/0001437749-25-007019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.